GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Net Income From Continuing Operations

NaviFUS (ROCO:6872) Net Income From Continuing Operations : NT$-69.57 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. NaviFUS's net income from continuing operations for the six months ended in Dec. 2023 was NT$-51.44 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-69.57 Mil.

NaviFUS Net Income From Continuing Operations Historical Data

The historical data trend for NaviFUS's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Net Income From Continuing Operations Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial -62.11 -63.07 -82.66 -63.52 -69.57

NaviFUS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.20 -26.42 -37.10 -18.13 -51.44

NaviFUS Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-69.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NaviFUS (ROCO:6872) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Net Income From Continuing Operations
Comparable Companies
ROCO:6850 ROCO:6810 ROCO:6610 ROCO:3205 ROCO:6709 ROCO:4192 ROCO:6827 ROCO:4186 ROCO:6652 ROCO:4195 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
Website
https://www.navifus.com
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines